Clinical trial
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
NCT00056199 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00056199 |
|---|---|
| Title | EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome |
| Official title | Pilot Study of Intravitreal Injection of EYE001 (Anti-VEGF Pegylated Aptamer) for Advanced Ocular Disease of Von Hippel-Lindau (VHL) Disease |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hippel-Lindau Disease |
| Intervention type | Drug |
| Interventions | EYE001 |
| Enrollment | 5 |
| Start date | Mar 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Mar 7, 2003 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: